Ribo partners with Insilico Medicine to accelerate AI-driven siRNA drug development

  • Suzhou Ribo Life Science entered strategic collaboration with Insilico Medicine on May 12, 2026 to accelerate siRNA drug development using AI.
  • Partnership targets AI-driven target discovery, siRNA design and optimization, AI-assisted development, clinical translation.
  • Ribo to pair its algorithm-based siRNA sequence design platform and ligand screening capabilities with Insilico’s end-to-end Pharma.AI drug discovery platform.
  • Collaboration expands earlier work between the companies in intelligent autonomous high-throughput screening, including use of Insilico’s LifeStar 2 automated laboratory platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605120830PR_NEWS_EURO_ND__EN57191) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.